TY - JOUR
T1 - What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?
AU - Komrokji, Rami
AU - Al Ali, Najla
AU - Padron, Eric
AU - Lancet, Jeffrey
AU - Nazha, Aziz
AU - Steensma, David
AU - DeZern, Amy
AU - Roboz, Gail
AU - Garcia-Manero, Guillermo
AU - Sekeres, Mikkael A.
AU - Sallman, David
N1 - Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Hypomethylating agents (HMAs) are the standard of care for higher risk MDS (HR-MDS) patients. The current dogma is to begin HMA therapy in all HR-MDS patients at the time of initial diagnosis. We investigated the impact of the timing of HMA initiation among HR-MDS patients presenting with adequate blood counts to discern the possible benefit of early treatment based solely on disease risk. We identified 320 HR-MDS patients with adequate hematopoiesis who were treated with HMA. The complete response rates were 21%, 26%, 23%, and 7% respectively for patients treated within 30, 31–60, 61–90, and more than 90 days from time of diagnosis (p=.046). The median OS from the date of diagnosis was 641, 550, 979, and 806 days, respectively (p=.2). A delay in initiating HMA therapy in HR-MDS patients with adequate blood counts is not associated with worsened outcomes.
AB - Hypomethylating agents (HMAs) are the standard of care for higher risk MDS (HR-MDS) patients. The current dogma is to begin HMA therapy in all HR-MDS patients at the time of initial diagnosis. We investigated the impact of the timing of HMA initiation among HR-MDS patients presenting with adequate blood counts to discern the possible benefit of early treatment based solely on disease risk. We identified 320 HR-MDS patients with adequate hematopoiesis who were treated with HMA. The complete response rates were 21%, 26%, 23%, and 7% respectively for patients treated within 30, 31–60, 61–90, and more than 90 days from time of diagnosis (p=.046). The median OS from the date of diagnosis was 641, 550, 979, and 806 days, respectively (p=.2). A delay in initiating HMA therapy in HR-MDS patients with adequate blood counts is not associated with worsened outcomes.
KW - Myelodysplastic syndromes
KW - higher risk disease
KW - hypomethylating agents
KW - optimal timing of treatment
UR - http://www.scopus.com/inward/record.url?scp=85107778015&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107778015&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.1938028
DO - 10.1080/10428194.2021.1938028
M3 - Article
C2 - 34114922
AN - SCOPUS:85107778015
SN - 1042-8194
VL - 62
SP - 2762
EP - 2767
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 11
ER -